Search
Guangshengtang Clarifies: Inclusion of GST-HG131 in Breakthrough Therapy List Does Not Imply Market Approval
4 day ago /
Read about 0 minute
Author：小编
Following the inclusion of Guangshengtang's innovative hepatitis B treatment drug, GST-HG131, in the breakthrough therapy list by the Center for Drug Evaluation of the National Medical Products Administration, the company's stock price saw a continuous surge. To clarify, Guangshengtang issued an announcement stating that this inclusion does not signify market approval and is not expected to have a significant impact on the company's performance in the short term. Additionally, the company's Phase III clinical trial for another drug, GST-HG141, has successfully received ethical review approval and has been duly registered and announced.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
